Publications by authors named "Patrick A Ott"

100Publications

The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.

Oncologist 2020 Jun 11;25(6):505-514. Epub 2020 Feb 11.

Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0659DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288631PMC
June 2020

Directing Traffic: How to Effectively Drive T Cells into Tumors.

Cancer Discov 2020 02 23;10(2):185-197. Epub 2020 Jan 23.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-0790DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007384PMC
February 2020

Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.

Clin Colorectal Cancer 2020 03 24;19(1):32-38.e3. Epub 2019 Sep 24.

Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2019.09.001DOI Listing
March 2020

Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma.

J Immunother Cancer 2019 11 7;7(1):289. Epub 2019 Nov 7.

Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0782-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836520PMC
November 2019

An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:e70-e78. Epub 2019 May 17.

4 Center for Cancer Research, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_238001DOI Listing
January 2019

Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy.

Front Oncol 2019 29;9:199. Epub 2019 Mar 29.

Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00199DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450051PMC
March 2019

Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors.

Cancer Discov 2019 04 12;9(4):476-481. Epub 2019 Mar 12.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-1357DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067230PMC
April 2019

Immunotherapy: An Old and New Modality for the Treatment of Cancer.

Authors:
Patrick A Ott

Hematol Oncol Clin North Am 2019 04 23;33(2):xi-xii. Epub 2019 Jan 23.

Melanoma Center & Center for Immuno-Oncology, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215-5450, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2019.01.001DOI Listing
April 2019

Intralesional Cancer Immunotherapies.

Authors:
Patrick A Ott

Hematol Oncol Clin North Am 2019 04 28;33(2):249-260. Epub 2019 Jan 28.

Department of Medical Oncology, Melanoma Center, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215-5450, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2018.12.009DOI Listing
April 2019

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.

Gynecol Oncol 2019 02 3;152(2):243-250. Epub 2018 Dec 3.

Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.11.017DOI Listing
February 2019

Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors.

Curr Oncol Rep 2018 11 15;21(1). Epub 2018 Nov 15.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana 2127, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0738-2DOI Listing
November 2018

A comparison of skin cancer screening and treatment costs at a Massachusetts cancer center, 2008 versus 2013.

J Am Acad Dermatol 2018 Nov 3;79(5):921-928. Epub 2018 Jul 3.

Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.06.045DOI Listing
November 2018

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.

J Clin Oncol 2018 10 15;36(28):2836-2844. Epub 2018 Aug 15.

Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6212DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161834PMC
October 2018

Immunotherapy: Immune-modified response criteria - an iterative learning process?

Authors:
Patrick A Ott

Nat Rev Clin Oncol 2018 05 13;15(5):267-268. Epub 2018 Mar 13.

Department of Medical Oncology, Dana Farber Cancer Institute, the Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2018.36DOI Listing
May 2018

Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.

Cancer 2018 03 3;124(6):1111-1121. Epub 2018 Jan 3.

Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31200
Publisher Site
http://dx.doi.org/10.1002/cncr.31200DOI Listing
March 2018

PD-1 inhibitors in endometrial cancer.

Oncotarget 2017 Dec 21;8(63):106169-106170. Epub 2017 Nov 21.

Patrick A. Ott: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22583DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739721PMC
December 2017

Towards personalized, tumour-specific, therapeutic vaccines for cancer.

Nat Rev Immunol 2018 03 11;18(3):168-182. Epub 2017 Dec 11.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nri.2017.131DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6508552PMC
March 2018

Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Cancer Discov 2018 02 3;8(2):196-215. Epub 2017 Nov 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-17-0833DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809290PMC
February 2018

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

J Clin Oncol 2017 Dec 2;35(36):4035-4041. Epub 2017 Nov 2.

Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.5471DOI Listing
December 2017

Reply to F. Tomao et al.

J Clin Oncol 2017 11 7;35(31):3633-3634. Epub 2017 Sep 7.

Patrick A. Ott, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; and Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.8681DOI Listing
November 2017

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.

J Clin Oncol 2017 Dec 16;35(34):3823-3829. Epub 2017 Aug 16.

Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Sandrine Hiret, ICO René Gauducheau, Nantes, France; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Anne Morosky, Sanatan Saraf, and Bilal Piperdi, Merck & Co, Kenilworth; and Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.5069DOI Listing
December 2017

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.

J Immunother Cancer 2017 08 15;5(1):66. Epub 2017 Aug 15.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave D1230, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://jitc.biomedcentral.com/articles/10.1186/s40425-017-02
Publisher Site
http://dx.doi.org/10.1186/s40425-017-0273-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557522PMC
August 2017

Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab.

J Immunother Cancer 2017 07 18;5(1):61. Epub 2017 Jul 18.

Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0259-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514538PMC
July 2017

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.

Oncology 2017 10;93(3):164-176. Epub 2017 Jun 10.

The Ronald O. Perelman Department of Dermatology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000475715DOI Listing
December 2017

Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.

J Neurooncol 2017 05;133(1):221

Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2485-xDOI Listing
May 2017

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.

J Clin Oncol 2017 Aug 10;35(22):2535-2541. Epub 2017 May 10.

Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Michael J. Pishvaian, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Hope S. Rugo, University of California San Francisco, San Francisco, CA; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick; Marion Carrigan, Sanatan Saraf, and Mei Chen, Merck, Kenilworth, NJ; Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea; Dominique Berton-Rigaud, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain; Jean-Charles Soria, Gustave Roussy and University Paris-Sud, Villejuif, France; Elena Elez, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Kyaw L. Aung, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and Juanita Lopez, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.5952DOI Listing
August 2017

Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.

Int J Radiat Oncol Biol Phys 2017 06 11;98(2):344-351. Epub 2017 Feb 11.

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2017.02.003DOI Listing
June 2017

Erratum to: Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.

Cancer Metastasis Rev 2017 03;36(1):51

Melanoma Disease Center and Center for Immuno-Oncology, Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA, 02215-5450, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-017-9665-1DOI Listing
March 2017

Combination immunotherapy: a road map.

J Immunother Cancer 2017 21;5:16. Epub 2017 Feb 21.

Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Z-1503, New York, NY 10065 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0218-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319100PMC
June 2018

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

Immunity 2017 02;46(2):197-204

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.immuni.2017.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408320PMC
February 2017

Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.

Cancer Metastasis Rev 2017 03;36(1):43-50

Melanoma Disease Center and Center for Immuno-Oncology, Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA, 02215-5450, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-017-9656-2DOI Listing
March 2017

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.

J Clin Oncol 2016 10;34(29):3562-3569

Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.1106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657013PMC
October 2016

Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.

J Neurooncol 2016 09 11;129(3):389-393. Epub 2016 Jul 11.

Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-016-2196-8DOI Listing
September 2016

Talimogene Laherparepvec for the Treatment of Advanced Melanoma.

Clin Cancer Res 2016 07 4;22(13):3127-31. Epub 2016 May 4.

Department of Medical Oncology, Melanoma Disease Center, and Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2709DOI Listing
July 2016

Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma.

J Immunother Cancer 2016 19;4:26. Epub 2016 Apr 19.

Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0129-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837591PMC
April 2016

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data.

Front Oncol 2015 22;5:202. Epub 2015 Sep 22.

Department of Medical Oncology, Melanoma Disease Center, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA , USA ; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA , USA.

View Article

Download full-text PDF

Source
http://journal.frontiersin.org/Article/10.3389/fonc.2015.002
Publisher Site
http://dx.doi.org/10.3389/fonc.2015.00202DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585112PMC
October 2015

Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.

Cancer Immunol Res 2015 Oct 22;3(10):1185-92. Epub 2015 Jun 22.

Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://cancerimmunolres.aacrjournals.org/cgi/doi/10.1158/232
Publisher Site
http://dx.doi.org/10.1158/2326-6066.CIR-15-0102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596761PMC
October 2015

Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.

Cancer Immunol Res 2015 Sep 5;3(9):986-91. Epub 2015 May 5.

Melanoma Disease Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0066DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561189PMC
September 2015

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

N Engl J Med 2015 May 20;372(21):2006-17. Epub 2015 Apr 20.

From Memorial Sloan Kettering Cancer Center (M.A.P., J.D.W.), Weill Cornell Medical College (M.A.P., J.D.W.), and New York University, Perlmutter Cancer Center (A.C.P.) - all in New York; J. Graham Brown Cancer Center, University of Louisville, Louisville, KY (J.C.); Institute Gustave Roussy, Villejuif (C.R.), Paris-Sud University, Orsay (C.R.), and Institut Universitaire du Cancer, Toulouse (N.M.) - all in France; Huntsman Cancer Institute, Salt Lake City (K.G.); Beth Israel Deaconess Medical Center (D. McDermott) and Dana-Farber Cancer Institute (P.A.O., F.S.H.) - both in Boston; Washington University in St. Louis, St. Louis (G.P.L.); Greenville Health System, Greenville, SC (J.K.G.); St. Luke's Cancer Center, Bethlehem, PA (S.S.A.); University of New Mexico, Albuquerque (M.S.); Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland (M.S.E.); California Pacific Center for Melanoma Research, San Francisco (D. Minor); Duke University, Durham, NC (A.K.S.); Oregon Health and Science University, Portland (M.T.); Bristol-Myers Squibb, Lawrenceville, NJ (C.H.); and Bristol-Myers Squibb, Wallingford, CT (L.M.R., P.G.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1414428DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744258PMC
May 2015

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma.

Oncotarget 2015 Feb;6(6):3479-92

Melanoma Disease Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414130PMC
http://dx.doi.org/10.18632/oncotarget.2980DOI Listing
February 2015

The biology and clinical development of MEK inhibitors for cancer.

Drugs 2014 Dec;74(18):2111-28

Melanoma and Developmental Therapeutics Clinics, University of Chicago Cancer Center, University of Chicago, 5841 S. Maryland Ave., MC2115, Chicago, IL, 60637, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-014-0315-4DOI Listing
December 2014

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

J Clin Oncol 2014 Nov 29;32(32):3659-66. Epub 2014 Sep 29.

Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.54.8115
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.8115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879709PMC
November 2014

New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy.

Drug Healthc Patient Saf 2014 24;6:77-88. Epub 2014 Jun 24.

Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DHPS.S39568DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075957PMC
July 2014

HLA-binding properties of tumor neoepitopes in humans.

Cancer Immunol Res 2014 Jun 3;2(6):522-9. Epub 2014 Mar 3.

Authors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, MassachusettsAuthors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, MassachusettsAuthors' Affiliations: Cancer Vaccine Center; Department of Medical Oncology, Dana-Farber Cancer Institute; The Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Massachusetts General Hospital; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; and Broad Institute of MIT and Harvard, Cambridge, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-13-0227DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049249PMC
June 2014

Vaccines and melanoma.

Hematol Oncol Clin North Am 2014 Jun 3;28(3):559-69. Epub 2014 Apr 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02215, USA; Cancer Vaccine Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2014.02.008DOI Listing
June 2014

Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function.

Front Immunol 2013 Oct 28;4:346. Epub 2013 Oct 28.

Dana Farber Cancer Institute, Harvard Medical School , Boston, MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2013.00346DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809567PMC
October 2013

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Clin Cancer Res 2013 Oct;19(19):5300-9

Authors' Affiliations: Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts; and Institut Gustave Roussy, Villejuif-Paris Sud, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0143DOI Listing
October 2013

Treatment for advanced melanoma: new drugs, new opportunities, new challenges.

Oncology (Williston Park) 2013 May;27(5):381-92, 391

Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
May 2013

Vemurafenib and radiation therapy in melanoma brain metastases.

J Neurooncol 2013 Jul 12;113(3):411-6. Epub 2013 Apr 12.

Department of Radiation Oncology, New York University Langone Medical Center, 566 First Avenue HC-107, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-013-1127-1DOI Listing
July 2013

Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.

Melanoma Res 2013 Jun;23(3):191-5

Department of Radiation Oncology, New York University Langone Medical Center, New York, New York 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0b013e32835f3d90DOI Listing
June 2013

The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention.

Chin Clin Oncol 2013 Mar;2(1)

Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2304-3865.2012.11.05DOI Listing
March 2013